Back

In silico Drosophila Patient Model Reveals Optimal Combinatorial Therapies for Colorectal Cancer

Chaudhary, S. U.; Gondal, M. N.; Butt, R. N.; Shah, O. S.; Nasir, Z.; Hussain, R.; Khawar, H.; Tariq, M.; Faisal, A.

2020-09-01 systems biology
10.1101/2020.08.31.274829 bioRxiv
Show abstract

In silico models of biomolecular regulation in cancer, annotated with patient-specific gene expression data can aid in the development of novel personalized cancer therapeutics strategies. Drosophila melanogaster is a well-established animal model that is increasingly being employed to evaluate preclinical personalized cancer therapies. Here, we report five Boolean network models of biomolecular regulation in cells lining the Drosophila midgut epithelium and annotate them with patient-specific mutation data to develop an in silico Drosophila Patient Model (DPM). The network models were validated against cell-type-specific RNA-seq gene expression data from the FlyGut-seq database and through three literature-based case studies on colorectal cancer. The results obtained from the study help elucidate cell fate evolution in colorectal tumorigenesis, validate cytotoxicity of nine FDA-approved cancer drugs, and devise optimal personalized drug treatment combinations. The proposed personalized therapeutics approach also helped identify synergistic combinations of chemotherapy (paclitaxel) with targeted therapies (pazopanib, or ruxolitinib) for treating colorectal cancer. In conclusion, this work provides a novel roadmap for decoding colorectal tumorigenesis and in the development of personalized cancer therapeutics through a DPM.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.